Mission
Partner with cancer organisations / institutes and selected industry players on real word-research and precision oncology
Collaborate on high-quality major European Research studies on real life data
Increase European trial access for care cancer patients profiled with large panel and Working Groups
Reduce the cost of clinical research applying innovative digital methods to accelerate insight into cancer care
Increase the speed of biomarker validation research and reduce health costs through digital innovation
Expand the value of precision medicine beyond access to high cost drugs
Partner with cancer organisations/institutes and selected industry players on real word-research and precision oncology
Enhancing cancer outcomes in Europe
and drive innovation through the building of a federated digital research infrastructure to perform protocolised observational studies, appropriate medical analytics or screening tools and support pragmatic trials.
Focus on gathering high-quality, up-to-date real-world data
on cancer diagnosis, treatment, outcomes, and other related conditions.
Creating digital interoperability
between its Members and Associate Members using high quality multisite real-world data.
Develop standards for files and network protocols
supporting them to improve data quality and completeness; new data sources and tools; novel digital enabled research methods (especially in biomarker development).
Actions
regional, national or international entity, public or private, including donations.
and support actions assigned by the European Commission, regional, national or international entities, public or private including donations.
preparing a new generation of scientists to real world studies.
and to develop and exploit intellectual property to build and operate that digital infrastructure and research network.
between its Members and Associate Members to standardise data collection, sharing protocols and best practices.
with regard to European, international or national bodies.
Support
Use routine EMR to drive outcomes research and advanced real world evidence such as external comparators (control to single arm trials)
Semi-automate trial screening to make it easier to recruit to trial, especially in precision oncology and so democratise trial access
Drive large scale Mendelian randomisation research and decision impact studies on large NGS panels linked to clinical data
Drive large scale collection of well annotated samples with deep clinical records for discovery and diagnostic development programmes
Ultimately, drive pragmatic platform trials in precision oncology
Create a formal link with patient organisations to empower them into research activities
